Home
Vyera Pharmaceuticals

Vyera Pharmaceuticals Market Share Analysis for May 2026

Health > Biotechnology and Pharmaceuticals

Domainvyera.com

Year Founded2015

Employees51 - 200

Annual Revenue$5M - $10M

Vyera Pharmaceuticals

Vyera Pharmaceuticals (including company regionals)

vyera.com

See more website traffic and engagement information

Vyera Pharmaceuticals Revenue up to May 2026 is 5M - 10M

revenue generated by Vyera Pharmaceuticals top domains

Vyera Pharmaceuticals top domains revenue over 3 years

Revenue for Vyera Pharmaceuticals top domains

vyera.com5M - 10M

See more with Sales Intelligence

Total visits to Vyera Pharmaceuticals's top domains

Understand Vyera Pharmaceuticals market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

vyera.com1K

See more with Sales Intelligence

Avg. visit duration in Vyera Pharmaceuticals's top domains

Analyze Vyera Pharmaceuticals engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Vyera Pharmaceuticals's top domains

See how Vyera Pharmaceuticals keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

vyera.com1.12

See more with Sales Intelligence

Vyera Pharmaceuticals top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Vyera Pharmaceuticals

These are the website technologies, by industry, used by Vyera Pharmaceuticals top domains

Advertising (3)

Google Adsense

Conversion & Analytics (2)

Google Analytics

Email Services (1)

Microsoft Exchange Online

Marketing (1)

Google Marketing Platform

More Technologies

2

See all

News & Signals from Vyera Pharmaceuticals

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsVyera acquired Daraprim Direct on Aug 1st '15.In August 2015, Vyera acquired Daraprim and increased the price dramatically overnight from $17.50 per pill to $750 per pill.

NewsVyera had issues with elaborate anticompetitive scheme to preserve a monopoly” on Daraprim on Jan 1st '20.In January 2020, the FTC launched a federal complaint against Vyera, alleging that the company engaged in an “elaborate anticompetitive scheme to preserve a monopoly” on Daraprim, which in turn allowed Vyera to hike the price of the medicine by over 4,000%.

NewsImpaxlabs sold assets to Vyera on Jan 1st '15.Vyera, founded in 2014 as Turing Pharmaceuticals, acquired Daraprim from Impax Laboratories Inc in 2015.